Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibrostop
- Development stage
- Phase 1
- Lead developer
- Birch BioMed
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Fibrostop refers to a pipeline of topical therapeutic candidates, including Fibrostop 1 (FS1) and Fibrostop 2 (FS2), designed to treat dermal fibroproliferative disorders such as hypertrophic scars and keloids. Fibrostop 1 is a formulation of the amino acid metabolite kynurenine, while Fibrostop 2 is based on kynurenic acid. These compounds are endogenous catabolites of tryptophan that act by stimulating the expression of Matrix Metalloproteinase-1 (MMP-1) and Matrix Metalloproteinase-3 (MMP-3) in dermal fibroblasts. This induction of MMPs facilitates the degradation of excess collagen deposits, which are the primary cause of raised, itchy, and red pathological scarring. Developed by researchers at the University of British Columbia, the FS2 formulation has been evaluated in Phase 1 clinical trials for safety and tolerability in healthy volunteers.
- Brand names
- Fibrostop 1Fibrostop1Fibrostop-1Fibrostop 2Fibrostop2Fibrostop-2
- Other names
- KynurenineKynurenic acid
02
Targets
MMP3 (Matrix metalloproteinase-3)MMP1 (Matrix metalloproteinase-1)
Beyond the preview
Go deeper on Fibrostop.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibrostop.